The FDA recently proposed scheduling synthetic and concentrated forms of 7-hydroxymitragynine, or 7-OH, under the Controlled ...

Zydus Lifesciences has secured a no objection certificate from Health Canada for its ZDS-Varenicline tablets, designed to aid ...

Ahmedabad: Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets ...

SAN DIEGO — Tavapadon, a novel and highly selective partial agonist of dopamine D1 and D5 receptors, significantly improved motor function without increasing impulse control disorders in ...

The study’s estimated primary completion date is June 2024. A second Synthekine cancer candidate, STK-012, is an IL-2 partial agonist using the engineered cytokine partial agonist platform.